Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency

Completed

Conditions: Exocrine Pancreatic Insufficiency
Pancreatic Diseases
Digestive System Diseases

Interventions: Drug: Lipacreon

Registration Number: NCT01427725

Lead Sponsor: Mylan Inc.

Brief Summary: This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients receiving the treatment with LipaCreon for a long term in order to evaluate the effective and safe use of LipaCreon.

Detailed Description: Criteria for evaluation:

1. Adverse events

2. Nutritional endpoints

* BMI (height \[only prior to the start of Lipacreon treatment\] and weight)

* Serum total protein

* Albumin

* Total cholesterol

* Triglycerides

* Haemoglobin

3. Symptoms related to exocrine pancreatic insufficiency

* Steatorrhoea

* Frequency of bowel movements

* Diarrhoea

* Foul stool odour

* Decreased appetite

* Abdominal distension

4. Patient's quality of life (QOL)

5. Degree of general improvement

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 579

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type: OBSERVATIONAL

Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Lipacreon	Lipacreon	In general, pancrelipase 600 mg/dose was orally administered immediately after a meal, 3 times a day. Also, the dose was adjusted appropriately according to the patient's condition.

Primary Outcome Measures

Name	Time	Method
Number of Patients With Adverse Drug Reaction	At week 52	An adverse event (AE) was defined as any unfavourable or unintended disease, or symptom or sign of such a disease, or abnormal laboratory finding that occurred in a patient who received Lipacreon, whether or not considered related to the medicinal product. Also, an AE for which the relationship with Lipacreon could not be ruled out was regarded as an adverse drug reaction (ADR). 1. Related : There is a temporal relationship between the use of the medicinal product and the onset of an AE, or a relapse with readministration,where other factors are less likely to be involved. 2. Relationship cannot be ruled out : There are other potential factors although there is a temporal relationship between the use of the medicinal product and the onset of an AE

Secondary Outcome Measures

Name	Time	Method
Patient's Quality of Life - Physical Health (Summary)	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. PCS8 score is calculated by the following formula (All summed). PCS8 score = (0.23024×SF8GH)+(0.40672×SF8PF)+(0.38317×SF8RP)+(0.33295×SF8BP)+(0.07537×SF8VT)+(-0.01275×SF8SF)+(-0.30469×SF8MH)+(-0.14803×SF8RE)+0.67371 The minimum value of PCS8 is 5.315, and the maximum value is 70.689. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Symptoms Related to Exocrine Pancreatic Insufficiency - Steatorrhoea	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following symptoms were assessed as those related to exocrine pancreatic insufficiency prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * Steatorrhoea (Yes/No) * Frequency of bowel movements (times/day) * Diarrhoea (Yes/No) * Foul stool odour (Yes/No) * Decreased appetite (Yes/No) * Abdominal distension (Yes/No)
Nutrition Endpoints - Total Cholesterol	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following nutritional endpoints were measured prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * BMI (height \[only prior to the start of Lipacreon treatment\] and weight) * Serum total protein * Albumin * Total cholesterol * Triglycerides * Haemoglobin
Degree of General Improvement	At week 52	It was assessed at 24 weeks after the start of Lipacreon treatment and at the end of the observation period, using the following 4 grades: Improved, unchanged, exacerbated, unassessable
Nutritional Endpoints - Serum Total Protein	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following nutritional endpoints were measured prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * BMI (height \[only prior to the start of Lipacreon treatment\] and weight) * Serum total protein * Albumin * Total cholesterol * Triglycerides * Haemoglobin
Patient's Quality of Life - General Health	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. SF8GH scores; 1:63.38, 2:58.54, 3:50.27, 4:40.40, 5:34.38, 6:26.89 The minimum value of SF8GH is 26.89, and the maximum value is 63.38. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Patient's Quality of Life - Physical Functioning	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. SF8PF scores; 1:53.54, 2:47.77, 3:41.45, 4:27.59, 5:16.69 The minimum value of SF8PF is 16.69, and the maximum value is 53.54. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Nutritional Endpoints - BMI	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following nutritional endpoints were measured prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * BMI (height \[only prior to the start of Lipacreon treatment\] and weight) * Serum total protein * Albumin * Total cholesterol * Triglycerides * Haemoglobin
Nutrition Endpoints - Albumin	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following nutritional endpoints were measured prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * BMI (height \[only prior to the start of Lipacreon treatment\] and weight) * Serum total protein * Albumin * Total cholesterol * Triglycerides * Haemoglobin
Nutrition Endpoints - Triglycerides	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following nutritional endpoints were measured prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * BMI (height \[only prior to the start of Lipacreon treatment\] and weight) * Serum total protein * Albumin * Total cholesterol * Triglycerides * Haemoglobin
Nutrition Endpoints - Haemoglobin	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following nutritional endpoints were measured prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * BMI (height \[only prior to the start of Lipacreon treatment\] and weight) * Serum total protein * Albumin * Total cholesterol * Triglycerides * Haemoglobin
Patient's Quality of Life - Role Physical	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. SF8RP scores; 1:54.09, 2:47.42, 3:40.65, 4:27.91, 5:21.80. The minimum value of SF8RP is 21.80, and the maximum value is 54.09. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Patient's Quality of Life - Body Pain	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. SF8BP scores; 1:60.35, 2:52.46, 3:46.10, 4:38.21, 5:31.59, 6:21.68. The minimum value of SF8BP is 21.68, and the maximum value is 60.35. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Symptoms Related to Exocrine Pancreatic Insufficiency - Foul Stool Odour	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following symptoms were assessed as those related to exocrine pancreatic insufficiency prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * Steatorrhoea (Yes/No) * Frequency of bowel movements (times/day) * Diarrhoea (Yes/No) * Foul stool odour (Yes/No) * Decreased appetite (Yes/No) * Abdominal distension (Yes/No)
Patient's Quality of Life - Mental Health (Summary)	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. MCS8 score is calculated by the following formula (All summed). MCS8 score = (-0.02020×SF8GH)+(-0.19972×SF8PF)+(-0.16579×SF8RP)+(-0.15992×SF8BP)+(0.16737×SF8VT)+(0.27264×SF8SF)+(0.57583×SF8MH)+(0.42927×SF8RE)+4.34744 The minimum value of MCS8 is 10.108, and the maximum value is 74.511. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Patient's Quality of Life - Vitality	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. SF8VT scores; 1:60.01, 2:53.74, 3:44.48, 4:38.51, 5:28.68. The minimum value of SF8VT is 28.68, and the maximum value is 60.01. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Patient's Quality of Life - Social Functioning	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. SF8SF scores; 1:55.14, 2:45.60, 3:37.65, 4:29.15, 5:26.00. The minimum value of SF8SF is 26.00, and the maximum value is 55.14. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Patient's Quality of Life - Mental Health	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. SF8MH scores; 1:56.93, 2:50.72, 3:44.94, 4:36.30, 5:27.59. The minimum value of SF8MH is 27.59, and the maximum value is 56.93. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Patient's Quality of Life - Role Emotional	Baseline, 8 weeks, 24 weeks, and 52 weeks	Baseline, 8 and 24 weeks after the start of treatment, and at the end of the observation period, the patient was asked to fill out the standard SF-8™ (1 month) to assess the patient's QOL, which was recorded in the survey form for this survey. SF-8™:The Medical Outcomes Study 8-Item Short-Form Health Survey (Japanese version). Items are as follows. Physical health (summary):PCS8, Mental health (summary):MCS8, General health:SF8GH, Physical functioning:SF8PF, Role physical:SF8RP, Body pain:SF8BP, Vitality:SF8VT, Social functioning:SF8SF, Mental health:SF8MH, Role emotional:SF8RE. SF8RE scores; 1:54.19, 2:48.04, 3:42.24, 4:31.42, 5:19.98. The minimum value of SF8RE is 19.98, and the maximum value is 54.19. Higher scores mean a better outcome. The means ± SD was calculated by summing the values at each time point.
Symptoms Related to Exocrine Pancreatic Insufficiency - Frequency of Bowel Movements	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following symptoms were assessed as those related to exocrine pancreatic insufficiency prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * Steatorrhoea (Yes/No) * Frequency of bowel movements (times/day) * Diarrhoea (Yes/No) * Foul stool odour (Yes/No) * Decreased appetite (Yes/No) * Abdominal distension (Yes/No)
Symptoms Related to Exocrine Pancreatic Insufficiency - Diarrhoea	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following symptoms were assessed as those related to exocrine pancreatic insufficiency prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * Steatorrhoea (Yes/No) * Frequency of bowel movements (times/day) * Diarrhoea (Yes/No) * Foul stool odour (Yes/No) * Decreased appetite (Yes/No) * Abdominal distension (Yes/No)
Symptoms Related to Exocrine Pancreatic Insufficiency - Decreased Appetite	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following symptoms were assessed as those related to exocrine pancreatic insufficiency prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * Steatorrhoea (Yes/No) * Frequency of bowel movements (times/day) * Diarrhoea (Yes/No) * Foul stool odour (Yes/No) * Decreased appetite (Yes/No) * Abdominal distension (Yes/No)
Symptoms Related to Exocrine Pancreatic Insufficiency - Abdominal Distension	Baseline, 4 weeks, 8 weeks, 24 weeks, and 52 weeks	The following symptoms were assessed as those related to exocrine pancreatic insufficiency prior to the start of Lipacreon treatment, 4, 8 and 24 weeks after the start of treatment, and at the end of the observation period. * Steatorrhoea (Yes/No) * Frequency of bowel movements (times/day) * Diarrhoea (Yes/No) * Foul stool odour (Yes/No) * Decreased appetite (Yes/No) * Abdominal distension (Yes/No)

Trial Locations

Locations (189): Research facility ID ORG-000216
🇯🇵
Aichi, Japan
Research facility ID ORG-000215
🇯🇵
Aichi, Japan
Research facility ORG-000096
🇯🇵
Aichi, Japan
Research facility ORG-000086
🇯🇵
Aichi, Japan
Research facility ORG-000120
🇯🇵
Aichi, Japan
Research facility ORG-000119
🇯🇵
Aichi, Japan
Research facility ID ORG-000208
🇯🇵
Aichi, Japan
Research facility ID ORG-000256
🇯🇵
Aichi, Japan
Site Reference ID/Investigator# 71098
🇯🇵
Akita, Japan
Site Reference ID/Investigator# 68378
🇯🇵
Chiba, Japan
Research facility ORG-000129
🇯🇵
Aomori, Japan
Research facility ORG-000222
🇯🇵
Akita, Japan
Research facility ORG-000133
🇯🇵
Aomori, Japan
Research facility ORG-000162
🇯🇵
Chiba, Japan
Site Reference ID/Investigator# 75790
🇯🇵
Chiba, Japan
site REference ID/Investigator# 75798
🇯🇵
Chiba, Japan
Research facility ID ORG-000246
🇯🇵
Chiba, Japan
Research facility ORG-000118
🇯🇵
Chiba, Japan
Research facility ID ORG-000251
🇯🇵
Ehime, Japan
Research facility ID ORG-000232
🇯🇵
Ehime, Japan
Research facility ORG-000233
🇯🇵
Ehime, Japan
Research facility ORG-000130
🇯🇵
Ehime, Japan
Research facility ID ORG-000271
🇯🇵
Fukui, Japan
Site reference ID/Investigator # 88674
🇯🇵
Fukui, Japan
Research facility ORG-000094
🇯🇵
Fukuoka, Japan
Research facility ID ORG-000269
🇯🇵
Fukuoka, Japan
Investigator ID 117496
🇯🇵
Fukuoka, Japan
Research facility ID ORG-000229
🇯🇵
Fukuoka, Japan
Research facility ORG-000088
🇯🇵
Fukuoka, Japan
Research facility ORG-000098
🇯🇵
Fukuoka, Japan
Research facility ORG-000091
🇯🇵
Fukuoka, Japan
Research facility ORG-000104
🇯🇵
Fukuoka, Japan
Research facility ORG-000165
🇯🇵
Fukuoka, Japan
Research facility ORG-000114
🇯🇵
Fukuoka, Japan
Research facility ID ORG-000262
🇯🇵
Fukuoka, Japan
Research facility ID ORG-000207
🇯🇵
Fukushima, Japan
Site Reference ID/Investigator# 84554
🇯🇵
Fukushima, Japan
Research facility ID ORG-000238
🇯🇵
Gifu, Japan
Research facility ORG-000136
🇯🇵
Fukushima, Japan
Site reference ID/Investigator# 91833
🇯🇵
Gifu, Japan
Research facility ORG-000139
🇯🇵
Gunma, Japan
Research facility ORG-000156
🇯🇵
Hiroshima, Japan
Site reference ID/Investigator # 84557
🇯🇵
Gunma, Japan
Research facility ID ORG-000272
🇯🇵
Gunma, Japan
Site reference ID/Investigator # 91835
🇯🇵
Hiroshima, Japan
Research facility ID ORG-000241
🇯🇵
Hiroshima, Japan
Site Reference ID/Investigator# 88698
🇯🇵
Hiroshima, Japan
Site Reference ID/Investigator# 84515
🇯🇵
Hiroshima, Japan
Research facility ID ORG-000203
🇯🇵
Hiroshima, Japan
Research facility ID ORG-000213
🇯🇵
Hokkaido, Japan
Research facility ID ORG-000220
🇯🇵
Hokkaido, Japan
Research facility ORG-000097
🇯🇵
Hokkaido, Japan
Site Reference ID/Investigator# 84535
🇯🇵
Hokkaido, Japan
Research facility ID/Investigator # ORG-000221 / 86896
🇯🇵
Hokkaido, Japan
Research facility ID ORG-000250
🇯🇵
Hokkaido, Japan
Site Reference ID# 84573
🇯🇵
Hokkaido, Japan
Research facility ID ORG-000211
🇯🇵
Hokkaido, Japan
Research facility ORG-000140
🇯🇵
Hokkaido, Japan
Research facility ORG-000142
🇯🇵
Hyogo, Japan
Research facility ID ORG-000223
🇯🇵
Hokkaido, Japan
Research facility ID ORG-000201
🇯🇵
Hokkaido, Japan
Research facility ORG-000159
🇯🇵
Hyogo, Japan
Site Reference ID/Investigator# 73816
🇯🇵
Hyogo, Japan
Research facility ID ORG-000225
🇯🇵
Hyogo, Japan
Research facility ORG-000152
🇯🇵
Hyogo, Japan
Site Reference ID/Investigator# 75804
🇯🇵
Ibaraki, Japan
Research facility ORG-000160
🇯🇵
Hyogo, Japan
Research facility ORG-000163
🇯🇵
Hyogo, Japan
Research facility ID ORG-000249
🇯🇵
Ibaraki, Japan
Research facility ID ORG-000181
🇯🇵
Ibaraki, Japan
Investigator ID 117498
🇯🇵
Ishikawa, Japan
Site Reference ID/Investigator# 63982
🇯🇵
Iwate, Japan
Research facility ORG-000107
🇯🇵
Kagoshima, Japan
Research facility ID ORG-000260
🇯🇵
Kagawa, Japan
Site reference ID/Investigator# 91860
🇯🇵
Kagoshima, Japan
Research facility ID ORG-000167
🇯🇵
Kanagawa, Japan
Research facility ID ORG-000244
🇯🇵
Kagoshima, Japan
Research facility ID ORG-000202
🇯🇵
Kanagawa, Japan
Research facility ID ORG-000273
🇯🇵
Kagoshima, Japan
Research facility ID ORG-000212
🇯🇵
Kanagawa, Japan
Research faciliity ORG-000099
🇯🇵
Kanagawa, Japan
Research facility ID ORG-000182
🇯🇵
Kanagawa, Japan
Research facility ID ORG-000191
🇯🇵
Kanagawa, Japan
Research facility ID ORG-000254
🇯🇵
Kanagawa, Japan
Research facility ID ORG-000255
🇯🇵
Kanagawa, Japan
Research facility ORG-000154
🇯🇵
Kochi, Japan
Research facility ID ORG-000166
🇯🇵
Kochi, Japan
Site reference ID/Investigator # 75789
🇯🇵
Kyoto, Japan
Site reference ID/Investigator # 75802
🇯🇵
Kanagawa, Japan
Research facility ORG-000113
🇯🇵
Kumamoto, Japan
Research facility ORG-000153
🇯🇵
Kyoto, Japan
Research facility ID ORG-000176
🇯🇵
Kyoto, Japan
Research facility ID ORG-000196
🇯🇵
Kyoto, Japan
Research facility ID ORG-000180
🇯🇵
Kyoto, Japan
Investigator ID 117503
🇯🇵
Kyoto, Japan
Research facility ID ORG-000237
🇯🇵
Mie, Japan
Research facility ID ORG-000194
🇯🇵
Kyoto, Japan
Research facility ORG-000105
🇯🇵
Mie, Japan
Research facility ORG-000147
🇯🇵
Miyagi, Japan
Research facility ORG-000093
🇯🇵
Miyagi, Japan
Site reference ID/Investigator # 84561
🇯🇵
Miyagi, Japan
Research facility ORG-000092
🇯🇵
Miyagi, Japan
Site Reference ID/Investigator# 84560
🇯🇵
Miyagi, Japan
Investigator ID 117508
🇯🇵
Miyazaki, Japan
Investigator ID 117507
🇯🇵
Miyazaki, Japan
Research facility ORG-000171
🇯🇵
Nagano, Japan
Site reference ID/Investigator# 96736
🇯🇵
Nagano, Japan
Research facility ORG-000109
🇯🇵
Nagano, Japan
Research facility ID ORG-000290
🇯🇵
Nagano, Japan
Research facility ORG-000115
🇯🇵
Nagano, Japan
Research facility ORG-000137
🇯🇵
Nagasaki, Japan
Site reference ID/Investigator # 71102
🇯🇵
Nara, Japan
Research facility ID ORG-000265
🇯🇵
Nara, Japan
Research facility ORG-000100
🇯🇵
Niigata, Japan
Research facility ORG-000102
🇯🇵
Niigata, Japan
Site reference ID/Investigator # 91856
🇯🇵
Okinawa, Japan
Research facility ID ORG-000193
🇯🇵
Niigata, Japan
Investigator ID 117497
🇯🇵
Oita, Japan
Site reference ID/Investigator # 91836
🇯🇵
Okayama, Japan
Research facility ORG-000106
🇯🇵
Oita, Japan
Research facility ORG-000268
🇯🇵
Okayama, Japan
Research facility ID ORG-000231
🇯🇵
Okayama, Japan
Research facility ORG-000117
🇯🇵
Osaka, Japan
Site Reference ID/Investigator# 86894
🇯🇵
Osaka, Japan
Research facility ORG-000095
🇯🇵
Osaka, Japan
Research facility ID ORG-000183
🇯🇵
Osaka, Japan
Research facility ORG-000090
🇯🇵
Osaka, Japan
Research facility ORG-000089
🇯🇵
Osaka, Japan
Research facility ID ORG-000204
🇯🇵
Saga, Japan
Research facility ORG-000157
🇯🇵
Saitama, Japan
Research facility ORG-000143
🇯🇵
Saitama, Japan
Research facility ID ORG-000189
🇯🇵
Saitama, Japan
Research facility ID ORG-000190
🇯🇵
Saitama, Japan
Research facility ID ORG-000173
🇯🇵
Saitama, Japan
Research facility ID ORG-000199
🇯🇵
Saitama, Japan
Site Reference ID/Investigator# 86895
🇯🇵
Saitama, Japan
Site reference ID/Investigator# 96739
🇯🇵
Saitama, Japan
Research facility ORG-000172
🇯🇵
Saitama, Japan
Research facility ORG-000116
🇯🇵
Shiga, Japan
Research facility ID ORG-000178
🇯🇵
Shimane, Japan
Research facility ID ORG-000253
🇯🇵
Shizuoka, Japan
Site reference ID/Investigator# 84576
🇯🇵
Shizuoka, Japan
Research facility ID ORG-000252
🇯🇵
Shizuoka, Japan
Site Reference ID/Investigator# 91834
🇯🇵
Shizuoka, Japan
Research facility ID ORG-000239
🇯🇵
Shizuoka, Japan
Research facility ORG-000126
🇯🇵
Tochigi, Japan
Research facility ORG-000124
🇯🇵
Tokyo, Japan
Research facility ORG-000108
🇯🇵
Tochigi, Japan
Research facility ORG-000146
🇯🇵
Tokyo, Japan
Research facility ORG-000132
🇯🇵
Tokyo, Japan
Research facility ORG-000121
🇯🇵
Tokyo, Japan
Research facility ORG-000164
🇯🇵
Tokyo, Japan
Site Reference ID/Investigator# 84578
🇯🇵
Tokyo, Japan
Investigator ID 117499
🇯🇵
Tokyo, Japan
Research facility ORG-000110
🇯🇵
Tokyo, Japan
Research facility ORG-000101
🇯🇵
Tokyo, Japan
Investigator ID 117504
🇯🇵
Tokyo, Japan
Site Reference ID/Investigator# 73824
🇯🇵
Tokyo, Japan
Investigator ID 117505
🇯🇵
Tokyo, Japan
Research facility ID ORG-000179
🇯🇵
Tokyo, Japan
Research facility ORG-000138
🇯🇵
Tokyo, Japan
Research facility ID ORG-000195
🇯🇵
Tokyo, Japan
Research facility ORG-000161
🇯🇵
Tokyo, Japan
Research facility ORG-000123
🇯🇵
Tokyo, Japan
Site Reference ID/Investigator# 75777
🇯🇵
Tokyo, Japan
Research facility ID ORG-000227
🇯🇵
Tokyo, Japan
Research facility ORG-000158
🇯🇵
Tokyo, Japan
Research facility ORG-000103
🇯🇵
Tokyo, Japan
Research facility ORG-000151
🇯🇵
Tokyo, Japan
Site reference ID/Investigator # 86913
🇯🇵
Tottori, Japan
Research facility ID ORG-000263
🇯🇵
Yamaguchi, Japan
Research facility ORG-000128
🇯🇵
Yamaguchi, Japan
Research facility ID ORG-000266
🇯🇵
Yamaguchi, Japan
Research facility ORG-000127
🇯🇵
Yamanashi, Japan
Research facility ID ORG-000214
🇯🇵
Aichi, Japan
Research facility ID ORG-000247
🇯🇵
Aichi, Japan
Site reference ID/Investigator# 88676
🇯🇵
Chiba, Japan
Site reference ID/Investigator # 75775
🇯🇵
Aichi, Japan
Site Reference ID/Investigator# 68371
🇯🇵
Akita, Japan
Research facility ID ORG-000177
🇯🇵
Fukushima, Japan
Research facility ORG-000155
🇯🇵
Hiroshima, Japan
Site reference ID/Investigator# 84575
🇯🇵
Hokkaido, Japan
Investigator ID 117501
🇯🇵
Tokyo, Japan
Research facility ORG-000122
🇯🇵
Yamagata, Japan
Research facility ID ORG-000243
🇯🇵
Wakayama, Japan
Research facility ORG-000135
🇯🇵
Saitama, Japan
Research facility ORG-000150
🇯🇵
Kyoto, Japan
Research faclity ORG-000112
🇯🇵
Kyoto, Japan
Research facility ORG-000267
🇯🇵
Niigata, Japan